Bain, Cinven to acquire specialty chemicals maker for $4.7bn

Private equity specialists Bain Capital and Cinven inked a deal to purchase the Specialty Ingredients unit (LSI) of Switzerland-based pharmaceuticals group Lonza for an enterprise value of CHF4.2 billion ($4.7 billion) in a transaction that is set to close in the second half of this year.

According to Lonza Chairman Albert Baehny, Bain and Cinven have shown an understanding of the value of the experience and expertise of the company’s employees and presented the “most compelling industrial strategy and vision for the business” and are keen to prioritize R&D and innovation . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available. Research articles require an Annual sub.

Get started

Related Articles

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!